Talisman Therapeutics is at the forefront of developing disease-modifying therapeutics for Alzheimer's and other neurodegenerative diseases, leveraging a cutting-edge human neuroscience discovery platform. This platform integrates human stem cell-derived neural cell types with human genetics to create advanced models that simulate disease initiation and progression. By utilizing induced pluripotent stem cell (iPSC) technology, Talisman addresses the limitations of traditional neurological drug discovery methods, significantly enhancing the potential for discovering effective treatments.

The company's discovery pipeline encompasses all stages of preclinical development, focusing on three primary areas: lysosome biology, pathogenic protein reduction, and microglial health. Talisman has a strong track record of collaborating with biotechs, venture capital firms, and global pharmaceutical companies, providing expertise to accelerate the progression of preclinical neuroscience programs. This collaborative approach not only supports Talisman's internal discovery initiatives but also fosters innovation within the broader neuroscience research community.

United Kingdom

Talisman Therapeutics is a human stem cell drug discovery company, based in Cambridge, UK. We are committed to revolutionising the discovery of treatments for Alzheimer’s disease (AD). Our novel human stem cell models of AD provide a transformative platform for rapid and more therapeutically relevant compound identification, thereby offering the potential to significantly accelerate drug discovery and, more importantly, de-risk subsequent development.

Nervous System Diseases

jonas webb building, babraham research campus, cambridge, england, united kingdom

Talisman Therapeutics

Company Details